Fulcrum Therapeutics, Inc. - 8-K Filing
Fulcrum Therapeutics announced a restructuring plan on May 31, 2026, following the discontinuation of pociredir for sickle cell disease development, which includes reducing its workforce by approximately 85% and incurring $4.2 million in charges related to severance and benefits. The company also initiated a strategic review process with financial advisor Leerink Partners LLC to explore options such as mergers or asset sales. (Items: 2.05 Costs Associated with Exit or Disposal Activities, 8.01 Other Events)
Tickers: $FULC